253 citations
,
April 2014 in “Drugs” This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.
39 citations
,
September 2015 in “Clinical Therapeutics” This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.
36 citations
,
June 2014 in “Experimental Neurology” This review outlines the main findings from clinical trials on teriflunomide's efficacy and safety for relapsing multiple sclerosis, noting clinical considerations and exploring its mechanisms based on various studies.
29 citations
,
January 2016 in “CNS drugs” This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.